31 results about "Triglyceride level" patented technology

The invention provides a preparation method of an apple water kefir beverage and application of the apple water kefir beverage in lowering cholesterol. The method comprises the following steps: preparing apple juice, activating water kefir grains, inoculating the activated water kefir grains into the apple juice, and fermenting to prepare the apple water kefir beverage. The volatile component change in the fermentation process is analyzed through GC-MS and GC-IMS systems, it is proved that the unique bouquet characteristic and flavor coordination of the apple water kefir beverage are improved through water kefir grain fermentation, and meanwhile the organic acid composition is optimized. A mouse model verifies that the apple water kefir beverage has the effect of reducing cholesterol, can reduce liver lipid droplets, total cholesterol, low-density lipoprotein and triglyceride levels, and also can regulate intestinal microbial communities (increase firmicobacteria, bacteroides and faecalis bacteria). The apple water kefir beverage disclosed by the invention has wide market potential and provides a scientific basis for the development of functional beverages.

An apparatus for measuring a triglyceride level includes: a sensor including: a plurality of peripheral light sources disposed at a periphery thereof, the plurality of peripheral light sources being configured to emit light toward an object, and a plurality of detectors each disposed at predetermined distances from the respective peripheral light sources of the plurality of peripheral light sources, the plurality of detectors being configured to detect optical signals reflected from or scattered by the object. The apparatus also includes a processor configured to selectively drive the plurality of peripheral light sources to obtain features based on the detected optical signals, and to measure the triglyceride level based on the obtained features.

Provided herein are anti-Activin E antibodies having specific complementarity determining regions (CDRs) for the heavy and light chains, heavy and light chains, antigen binding fragments thereof, polynucleotides that encode the same, vectors, and host cells, and methods for treating a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and / or heart failure with the anti-Activin E antibodies disclosed herein.

The present invention relates to an orally administrable nutraceutical composition comprising omega- 3 fatty acids, at least one plant-derived extract exhibiting hypolipidemic activity, and an antioxidant. Hie composition is formulated as a nanoemulsion to enhance bioavailability, improve gastrointestinal absorption, and increase the therapeutic efficacy of the active compounds. The synergi stic interaction between omega- 3 fatty-7 acids and the bioactive component of plant extract promotes significant reduction in blood plasma triglyceride levels, supporting cardiovascular health. Hie formulation demonstrates improved pharmacokinetic parameters, including enhanced systemic exposure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), compared to commercially available omega- 3 supplements, including increased bioavailability under both fasted and fed conditions. This invention offers a novel strategy for enhancing the therapeutic efficacy of omega- 3 fatty acids in the management of cardiovascular diseases.

The invention discloses application of physcion in preparation of a medicine for reducing liver cell lipid deposition, and particularly relates to application of physcion in preparation of a medicine for preventing and treating lipid deposition fatty liver. In-vitro cell experiments prove that the physcion shows low toxicity and a wide safety range in a human normal hepatocyte line THLE3, a human hepatoma cell line HepG2 and a mouse normal hepatocyte line AML12, and can obviously reduce the level of oleic acid-induced intracellular triglyceride in a dose-dependent manner, so that the physcion can be used for preparing a medicine for treating liver cancer. Oil red O staining results also visually show that lipid droplet accumulation in cells can be effectively reduced; according to the invention, the technical prejudice that the emodin monomethyl ether is regarded as a potential hepatotoxic component in the prior art is overcome, a safe and effective new choice is provided for the treatment of the lipid deposition fatty liver, and the pharmaceutical composition has a wide clinical application prospect.

The invention discloses a strain for regulating and controlling intestinal fatty acid absorption as well as a screening method and application thereof. The screening method of the bacterial strain comprises the following steps: (1) carrying out intragastric administration on an SPF-level mouse by 100 mu L of a wild boar excrement suspension with the concentration of 10g / 100mL to colonize a wild boar excrement flora; 2) performing 16S rRNA sequencing to detect differential intestinal flora, and detecting and analyzing the difference of relative abundance of each species through a Kruscal-Wallis rank sum to obtain a strain which is in negative correlation with fatty acid metabolism (including but not limited to a plurality of indexes such as weight, adipose tissue quality, serum total triglyceride level, serum total cholesterol level and the like). The bacterial strain Rombout ilealis is preserved in the China Center for Type Culture Collection, the preservation date is September 12, 2025, and the preservation number is CCTCC (China Center for Type Culture Collection) M 20252008. The invention relates to a feed probiotic additive for regulating and controlling intestinal fatty acid absorption. The functional effect of R.ilealis in lipid metabolism is provided for the first time, and a new probiotic screening method is provided for controlling absorption of fatty acid in the intestinal tract.

The present invention relates to a pharmaceutical composition comprising a polypeptide, and more particularly, to a pharmaceutical composition for preventing or treating obesity, diabetes, or non-alcoholic fatty liver disease. The pharmaceutical composition is safe without any side effects such as vomiting or nausea and has the effects of reducing food intake, enhancing insulin secretion, inhibiting gastric emptying, promoting lipolysis and reducing triglyceride levels.

The application discloses application of calyculostero in preparation of blood sugar reducing drugs, and belongs to the technical field of pharmacological action of calyculostero. Experimental results show that the calyculostero can inhibit the activity of pancreatic alpha-amylase (IC50 is 4.34+ / -1.10 ug / mL) in a dose-dependent manner, reduce postprandial blood sugar, and improve sugar tolerance, reduce fasting blood sugar, improve total cholesterol and triglyceride levels, and reduce histopathological changes of liver, pancreas and kidney in long-term intervention, and has no obvious hepatotoxicity. The calyculostero can be used alone or together with a pharmaceutically acceptable excipient to prepare a pharmaceutical composition, and is used for reducing blood sugar or treating diabetes, and the dosage form includes oral preparations, injections and the like. The application provides a new natural medicine selection for drug treatment of diabetes.

The application discloses a plant lactobacillus gasseri strain capable of transforming ginsenoside and cassia glycoside, and application of the strain in lipid reduction and alleviation of fatty liver, and belongs to the fields of microbial technology, medicine and functional food. The core feature of the strain is that the strain can not only transform ginsenoside Rb1 into ginsenoside Rd with higher activity, but also transform cassia glycoside into cassia glycoside base, thereby improving the efficacy. The animal experiment proves that the strain and the corresponding substrate are combined to play a better role in lipid reduction and liver protection: the serum total cholesterol and triglyceride levels of high-fat diet mice can be effectively reduced, and the liver weight, liver lipid deposition and liver tissue fatty degeneration can be reduced and improved. The strain provides a new core strain and technical scheme for developing microecological preparations for preventing and / or assisting in treating hyperlipidemia, non-alcoholic fatty liver and other metabolic diseases.

The present application belongs to the field of analytical chemistry and electrochemistry, and particularly relates to an electrochemical sensor, a preparation method and application thereof in detection of sweat triglyceride content. A wearable sensor is prepared based on C-ZIF-67 / KB nanocomposite material, the sensor realizes detection of sweat triglyceride for the first time, and it is verified that sweat triglyceride level has high correlation with blood triglyceride level (correlation coefficient is 0.813, n=35). Through verification of a commercial colorimetric analysis kit, the sensor obtains a high correlation coefficient of 0.853 in detection of sweat triglyceride, which shows excellent accuracy.

The invention discloses a medium-chain and long-chain fatty acid grease-probiotic composition and application thereof in regulating blood sugar and blood lipid, the composition comprises a grease component and a probiotic component, the grease component takes myristic acid as main fatty acid, MA accounts for 50-70% of the total amount of fatty acid in grease, and the grease component is compounded with medium-chain triglyceride and high-oleic-acid sunflower seed oil. And the probiotic component is bifidobacterium pseudocatenum, and the viable count of the bifidobacterium pseudocatenum is preferably 1 * 10 < 9 >-1 * 10 < 11 > CFU / g. Animal experiments verify that the composition can significantly reduce fasting blood-glucose, improve oral glucose tolerance damage and significantly reduce serum total cholesterol and triglyceride levels. Compared with single use of MA grease or single use of Bifidobacterium pseudocatenuicola, the composition provided by the invention shows a better comprehensive effect in the aspects of regulating blood sugar and blood fat, can be applied to functional foods, nutritional supplements and pharmaceutical preparations, and is used for preventing or assisting in improving abnormal glucose and lipid metabolism.

The present application relates to a pharmaceutical composition comprising a polypeptide, and more particularly, to a pharmaceutical composition for preventing or treating obesity, diabetes, or non-alcoholic fatty liver disease. The pharmaceutical composition is safe without any side effects such as vomiting or nausea and has an effect of reducing food intake, enhancing insulin secretion, inhibiting gastric emptying, promoting lipolysis, and lowering triglyceride levels.

The present application relates to the technical field of biotechnology, and discloses a plant Lactobacillus plantarum XKFY202518 and application of the plant Lactobacillus plantarum XKFY202518 in preparation of a type 2 diabetes auxiliary preparation for improving insulin resistance and regulating blood lipid, the plant Lactobacillus plantarum XKFY202518 has a preservation number of CGMCC No.34745 in China General Microbiological Culture Collection Center, and a preservation date of June 3, 2025.The plant Lactobacillus plantarum XKFY202518 separated by the present application can effectively reduce the fasting blood glucose level, insulin level, total cholesterol level, triglyceride level, low-density lipoprotein cholesterol level, alanine aminotransferase level and aspartate aminotransferase level of a diabetic mouse, and increase the high-density lipoprotein cholesterol level of the mouse serum, thereby improving the hyperglycemia and hyperlipidemia symptoms of a type 2 diabetes mouse.

Provided herein are anti-Activin E antibodies having specific complementarity determining regions (CDRs) for the heavy and light chains, heavy and light chains, antigen binding fragments thereof, polynucleotides that encode the same, vectors, and host cells, and methods for treating a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and / or heart failure with the anti-Activin E antibodies disclosed herein.

A herbal composition for the treatment of a variety of metabolic disorders in mammals, especially human beings, is disclosed. A method of preparing the herbal composition is also disclosed. The herbal composition treats and alleviates a plurality of metabolic disorders, including central obesity, high blood pressure levels, high blood sugar levels, stress-induced fatigue, and type 2 diabetes. The herbal composition comprises the extracts of Dolichos lablab, Achyranthes aspera, and at least one of Cinnamomum zeylanicum and Cinnamomum cassia. The aforementioned extracts are present in the herbal composition at a predetermined weight range. The aforementioned extracts are standardized to contain active compounds, including proanthocyanidins, saponins, polyphenols, and tannins, in a predetermined concentration and in predetermined purity levels. The herbal composition causes an enhancement of adiponectin levels and high-density lipoprotein (HDL) levels, and a reduction in the accumulation of adipose tissue, total cholesterol levels, triglyceride levels, and low-density lipoprotein (LDL) levels.

The invention discloses bifidobacterium adolescentis and application of the bifidobacterium adolescentis in fat reduction. The bifidobacterium adolescentis is preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.31381. The bifidobacterium adolescentis has the effects of reducing the body fat rate, reducing weight, inhibiting the body weight rebound after weight loss, maintaining the weight loss effect, improving the blood fat and the like, promotes brown fat to produce heat and promotes white fat to be converted into brown fat, and meanwhile has high safety superior to that of weight-reducing drugs. In addition, when the medicine or food is used for treating and preventing obesity, the total cholesterol and total triglyceride levels are reduced, the liver function is improved, the pancreas health is maintained, the fat cell area is reduced, liver fat infiltration is reduced, the intestinal flora is regulated, and the inflammation level is reduced.

The invention discloses a parabacteroides gore DZ001 strain with a cholesterol sulfation function and application of the parabacteroides gore DZ001 strain. The preservation number of the parabacteroides gore DZ001 is GDMCC No: 67376, and the preservation number of the parabacteroides gore DZ001 is H. The strain is separated from faeces of healthy people, a genome carries a sequence for coding sulfotransferase, cholesterol can be specifically catalyzed to generate cholesterol sulfate with higher water solubility, intestinal epithelium reabsorption is blocked, and faeces excretion is promoted. In-vitro experiments show that the strain has excellent cholesterol degradation capacity, gastrointestinal tract tolerance and safe gamma-hemolysis characteristics; in-vivo experiments prove that the traditional Chinese medicine composition can remarkably reduce serum total cholesterol and triglyceride levels of high-fat diet mice, increase high-density lipoprotein cholesterol, improve liver fatty degeneration and regulate blood glucose metabolism. The strain and viable bacteria, supernate or cell-free extract thereof can be widely applied to preparation of cholesterol-reducing health-care foods, medicines and animal feeds, and a new way is provided for prevention and treatment of hypercholesterolemia and related cardiovascular and cerebrovascular diseases.

The invention provides cat-source enterococcus faecalis ZYpet-013 with cholesterol lowering activity and application of the cat-source enterococcus faecalis ZYpet-013. The cat-source enterococcus faecalis ZYpet-013 is derived from intestinal tracts of healthy pet cats, and the preservation number of the cat-source enterococcus faecalis ZYpet-013 is CGMCC No. 32009. The enterococcus faecalis ZYpet-013 is used for preparing products for degrading cholesterol, a cat food spraying composition stably loading the strain and a low-temperature spraying process are developed in a matched mode, the cat food with the cholesterol reducing function is prepared, through daily feeding, the levels of serum total cholesterol and triglyceride of pet cats are safely and effectively reduced, blood fat metabolism is improved, and the cholesterol reducing function is achieved. The requirements of industrial production and shelf life stability are met.

The invention belongs to the technical field of biological medicines, and discloses a novel application of an epimedium aqueous extract, icariin and icaritin in improvement of senescence-related fat accumulation and redistribution. The invention constructs a nematode-mouse dual verification model: firstly, in a caenorhabditis elegans model, it is found that the active ingredients can significantly reduce fat droplet accumulation and triglyceride level in senescence nematode bodies, and especially under the concentration of 50 [mu] M, icariin can reduce the triglyceride content of 15-day-old senescence nematode to 37.58% of a control group. Furthermore, a naturally aged mouse is evaluated by utilizing a high-resolution Micro-CT (VivaCT 80) living body imaging technology, and three-dimensional reconstruction and quantitative analysis prove that the medicine can remarkably reduce the volume of visceral fat in the abdomen of the aged mouse, effectively improve the ratio of visceral fat to subcutaneous fat (VAT / SAT ratio) and reverse central obesity caused by aging. The raw materials are from natural plants, have no obvious toxic or side effect after long-term administration, can accurately improve fat space distribution of aging organisms, and have significant clinical application value.

The application discloses a plant lactobacillus CCFM1486 transformed with siania glycoside, which can enhance lipid-lowering, weight loss and relieve liver lipid accumulation, and application thereof. The strain is preserved in the Guangdong Microbial Culture Collection Center, and the preservation number is GDMCC No: 66133. The core of the application is that the strain exhibits a significant synergistic effect when combined with siania glycoside: not only can it efficiently generate siania glycoside, but also can significantly inhibit weight gain caused by high-fat diet, reduce serum total cholesterol and triglyceride levels, and target to reduce liver lipid deposition and improve liver tissue fatty degeneration, and the effect is better than that of using siania glycoside alone. The live bacteria, fermented siania glycoside and combined preparation prepared based on the strain can be used for developing innovative products for preventing and / or assisting in treating obesity, hyperlipidemia and non-alcoholic fatty liver.

This invention belongs to the field of biomedical technology, specifically relating to an isoflavone compound, its preparation method, and its application. This compound is derived from *Rotenoporosis capillaris* (a type of vine). Derris eriocarpa The stem of *Derris fusiforme* was analyzed using 1D and 2D nuclear magnetic resonance (NMR) spectra (1H NMR, 1C NMR, and high-resolution mass spectrometry), and its structural formula is shown below: Chemical name: 5-hydroxy-6-(2"-hydroxy-3"-methylbut-3"-enyl)-3-(4'-hydroxyphenyl)-7-methoxyisoflavone. Screening using the Sci-finder database revealed that this compound is a novel isoflavone, isolated for the first time from *Derris fusiforme*. Lipid-lowering activity experiments showed that at the same drug concentration (25 μg / mL) as the positive control, it significantly reduced intracellular total cholesterol and triglyceride levels. p <0.001). Therefore, this novel isoflavone compound can be used to prepare drugs, health products, functional foods, or special medical foods for the prevention or treatment of hypertriglyceridemia, hyperlipidemia, obesity, or metabolic syndrome.

The application belongs to the field of traditional Chinese medicines, and particularly relates to a Yincheng Qushi traditional Chinese medicine composition, a preparation method thereof and application. The Yincheng Qushi traditional Chinese medicine composition comprises the following raw medicinal materials in parts by mass: 30-60 parts of Poria cocos, 10-30 parts of Atractylodes, 10-30 parts of Polyporus, 10-30 parts of Ramulus Cinnamomi, 5-10 parts of dried ginger, 10-30 parts of licorice, 10-30 parts of Artemisia, and 10-30 parts of North Adenophora. Clinical tests show that the Yincheng Qushi traditional Chinese medicine composition can effectively reduce the BMI of a wetness syndrome population, effectively improve the wetness syndrome level, obviously reduce the waist circumference and hip circumference, and has a certain weight loss trend, can significantly down-regulate the triglyceride level and up-regulate the high-density lipoprotein cholesterol level, can obviously reduce the systolic pressure and diastolic pressure level, and has good safety. Therefore, the Yincheng Qushi traditional Chinese medicine composition has good therapeutic effect on the wetness syndrome metabolic syndrome.

The invention discloses a beta-lactoglobulin-procyanidine covalent complex as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The compound is prepared by an alkali treatment method which comprises the following steps: mixing beta-lactoglobulin and procyanidine according to a mass ratio of 5: 1, reacting for 24 hours under the conditions that the pH is 9.0 and the room temperature is dark, neutralizing, dialyzing and freeze-drying to obtain the compound. The preparation process is simple, and conditions are mild. The obtained compound has good biological safety and remarkable activity of resisting the non-alcoholic fatty liver disease, and can effectively inhibit lipid deposition of hepatocytes, reduce the total cholesterol and triglyceride level of serum of the hepatocytes and mice and improve the blood lipid spectrum (reducing LDL-c and increasing HDL-c). The traditional Chinese medicine composition is natural in raw materials and remarkable in effect, and has the potential of being developed into drugs for preventing and / or treating the non-alcoholic fatty liver disease and related lipid metabolism disorders.

The present application relates to a kind of maltose-O-acyltransferase mutant MATM3, acetylated naringenin-7-O-glucoside and its preparation method and application in preparation of weight loss product.The maltose-O-acyltransferase mutant MATM3 of the present application, glutamic acid in the 125th position is mutated to alanine based on MAT enzyme, and the recombinant strain containing the maltose-O-acyltransferase mutant MATM3 can convert naringenin-7-O-glucoside into acetylated naringenin-7-O-glucoside, acetylated naringenin-7-O-glucoside can inhibit the mitotic clonal proliferation and lipid droplet accumulation of 3T3-L1 adipocyte, reduce triglyceride level, and play a good weight loss and fat loss effect.

The invention discloses a blood fat reducing composition containing supramolecular group composite peptide, which is composed of raw materials and basic energy substrates, the raw materials comprise supramolecular group composite peptide, natto freeze-dried powder, black pepper extract and bamboo leaf flavone, and the basic energy substrates comprise proteins, dietary fibers, fatty acids and / or lipids; the composite peptide is composed of soybean peptide and bitter gourd peptide. The composition prepared by compounding the components of specific types and dosages has the effects of remarkably reducing the triglyceride level, reducing the content of low-density lipoprotein cholesterol and increasing the content of high-density lipoprotein cholesterol, and part of the composition can also cooperate with statin western medicines (such as atorvastatin calcium) to achieve the effects of enhancing the effect of reducing blood fat and improving the blood fat content. The effect of assisting in improving or preventing and reducing blood fat is achieved. Therefore, the method can be used for developing functional foods and medicines and has a considerable market prospect.

The application belongs to the technical field of preoperative management of weight loss surgery, and particularly relates to a preoperative training system for obese patients and application thereof. The application provides a preoperative training system for obese patients, which comprises a physiological system evaluation module, a movement planning module and a nutrition module. The preoperative training system according to the application can significantly reduce the fasting blood glucose level, triglyceride level and low-density lipoprotein cholesterol level of obese patients after metabolic and weight loss surgery, thereby effectively improving the metabolic disorder of the patients, which has important clinical significance for improving the postoperative recovery process of obese patients, improving the quality of life and consolidating the long-term efficacy of weight loss surgery. The preoperative training system according to the application fills the technical gap in the preoperative management of obese patients, provides a non-invasive and efficient auxiliary system, and has a broad clinical application prospect.

This invention discloses the application of acyl-resorcinol derivatives in the preparation of drugs or health products for the prevention and treatment of non-alcoholic steatohepatitis (NASH). Studies have shown that in an in vitro model of free fatty acid-induced normal human hepatocytes, these compounds can exert a hepatoprotective effect by reducing lipid accumulation in cells. The representative compound, hyperacmotone A, significantly reduces lipid accumulation in cells in a dose-dependent manner and regulates the expression of genes such as Pparα, Cpt1, and Fapp1. In a methionine-choline deficiency-induced mouse model, administration of hyperacmotone A can inhibit hepatic steatosis, reduce serum alanine aminotransferase (ALT) and / or aspartate aminotransferase (AST) levels, while simultaneously reducing hepatic triglyceride levels and increasing hepatic glutathione activity. This suggests a certain preventive and therapeutic effect on the occurrence and development of NASH.

The invention relates to the technical field of biology, in particular to a protaetia brevitarsis insulin-like peptide gene and application thereof. The invention provides a protaetia brevitarsis type insulin peptide gene. The protaetia brevitarsis type insulin peptide gene is a PbILP2 gene or a PbILP7 gene; the nucleotide sequence of the PbILP2 gene is as shown in SEQ ID NO. 1; the nucleotide sequence of the PbILP7 gene is as shown in SEQ ID NO. 2. The protaetia brevitarsis insulin-like peptide gene disclosed by the invention can regulate and control lipid metabolism of protaetia brevitarsis larvae and the triglyceride level of the protaetia brevitarsis larvae.

This invention discloses the application of Xinnaoning capsules in the preparation of drugs for treating non-alcoholic fatty liver disease (NAFLD), belonging to the field of pharmaceutical technology. Using a high-fat diet-induced NAFLD model in SD rats, this invention demonstrates that Xinnaoning capsules can significantly reduce liver and serum total cholesterol and triglyceride levels, lower alanine aminotransferase (ALT) and aspartate aminotransferase (AST) to protect liver function, downregulate inflammatory factors such as tumor necrosis factor-α, interleukin-6, and interleukin-1β, improve insulin resistance, and alleviate hepatic steatosis and inflammatory damage in a dose-dependent manner, with higher doses showing better effects. This invention provides a safe, multi-target traditional Chinese medicine treatment for NAFLD, expands the clinical indications of Xinnaoning capsules, and has significant academic value and clinical application prospects.

The application discloses the technical field of lipid-lowering tea, and discloses a compound lipid-lowering tea and a preparation method thereof.The compound lipid-lowering tea comprises 10g of cassia seed, 5-15g of gynostemma pentaphyllum, 5-15g of salvia miltiorrhiza, 5-15g of hawthorn and 5-15g of bidens pilosa.The lipid-lowering active ingredients in medicinal materials, such as tanshinone, flavone, ursolic acid and anthraquinone, are studied, and it is clear that these ingredients play a lipid-lowering role through multiple signal pathways, such as the PI3K-AKT signal pathway, the cancer pathogenesis pathway and the estrogen signal pathway.Among them, the flavone is combined with the core target point PPARG, the anthraquinone is combined with HSP90AA, the ursolic acid is combined with ESR1, the lipid synthesis and metabolism are regulated, the fat index, the serum low-density lipoprotein and the triglyceride level are reduced, and the synthesis of high-density lipoprotein is promoted.The animal experiment verifies that the lipid-lowering tea has a significant lipid-lowering effect, and has no adverse effect on the organs of mice, thereby providing a new safe and effective lipid-lowering option for patients with hyperlipidemia.